Dupilumab new treatment option for moderate-to-severe asthma in kids: NEJM Hina Zahid16 Dec 2021 9:00 AM ISTA new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic...
Benralizumab, dupilumab improve sense of smell in chronic rhinosinusitis with nasal polyps: Study Medha Baranwal9 Nov 2021 10:30 AM ISTDelhi: Dupilumab and benralizumab both improved sense of smell in patients having chronic rhinosinusitis with nasal polyps (CRSwNP), also,...
Dupilumab use in Severe Atopic Dermatitis may induce two types of Ocular Surface Diseases Dr. Shravani Dali30 Oct 2021 9:00 AM ISTTwo types of Ocular Surface Diseases were found induced by Dupilumab in Severe Atopic Dermatitis, according to a study published in the Ophthalmology...
FDA approves dupilumab for children aged 6 to 11 years with moderate-to-severe asthma Hina Zahid22 Oct 2021 9:15 AM ISTThe US food and drug administration has expanded approval of dupilumab for moderate to severe asthma in children between 6 to 11 years.The approval is...
Compared to Dupilumab Upadacitinib rapidly improves itching and clears skin in atopic dermatitis: JAMA Dr Manoj Kumar Nayak9 Aug 2021 9:00 AM ISTUpadacitinib vs Dupilumab in adult atopic dermatitis (AD) : JAMA studyAtopic dermatitis is a severely pruritic relapsing disorder with multiple...
Dupilumab significantly improves itch and hives in chronic spontaneous urticaria patients: Study Hina Zahid5 Aug 2021 9:00 AM ISTUSA: Adding Dupixent (dupilumab) to standard-of-care antihistamines significantly reduced itch and hives in patients with moderate-to-severe chronic...
Dupilumab may Raise Risk of Ocular Disease in Atopic Dermatitis Patients: Study Josepha James8 Jun 2021 9:15 AM ISTDupilumab is the first human monoclonal antibody approved for the treatment of atopic dermatitis (AD). However, a recent study suggests that the use...
Dupilumab helps reduce exacerbations in kids with moderate-to-severe asthma: VOYAGE trial Hina Zahid29 May 2021 9:00 AM ISTNew York, NY: Dupilumab (Dupixent) significantly reduced exacerbations in patients aged 6 to <12 years with uncontrolled, moderate-to-severe...
Eczema Treatment linked with Development of Conjunctivitis, reveals study MD Bureau26 May 2021 9:00 AM ISTAtopic dermatitis (AD) is a common, chronic, inflammatory skin condition that affects up to 25% of children and 5% of adults worldwide. In a recent...
Sanofi wins EU approval for Dupixent for atopic dermatitis in children Ruchika Sharma1 Dec 2020 12:50 PM ISTDupixent is the only systemic medicine approved in the EU to treat these patients.
Dupilumab reduces severe attacks in asthmatic children, finds study Medha Baranwal14 Oct 2020 9:18 PM ISTDelhi: Dupilumab (Dupixent) significantly reduces severe asthma attacks in children with moderate-to-severe asthma, finds a recent study.The...
Sanofi Dupixent gets USFDA Breakthrough Therapy designation to treat eosinophilic esophagitis Ruchika Sharma16 Sept 2020 1:51 PM ISTParis: Drug major, Sanofi has recently secured Breakthrough Therapy designation from the U.S. Food and Drug Administration(USFDA) for its Dupixent (...
